Newsletter

Biotech Stocks

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we've looked at Ozempic and other GLP-1 Drugs. Investors paid a lot of attention to them in 2023, particularly those invested in companies with potential to be impacted directly or indirectly. The industry has come a fair way in the past couple of years and…

ByNick SundichJanuary 6, 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead! What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026! Note: These…

ByNick SundichJanuary 2, 2026

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…

ByNick SundichDecember 24, 2025

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB) closed at A$2.91 last Friday, up 27% over the past month as investors position ahead of the company's expected US$30 million-plus Q2 revenue report. The share price is now close to its January high of…

ByUjjwal MaheshwariDecember 22, 2025

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is among the largest reported under Australia’s R&D Tax Incentive program. The finding means Recce's international clinical programs now qualify for the government's 43.5% tax rebate…

ByUjjwal MaheshwariDecember 17, 2025

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called CYP-001 for acute graft versus host disease (aGvHD), a potentially life-threatening complication that affects up to 50 per cent of bone marrow transplant patients. With 65 participants now enrolled across clinical centres in the US,…

ByUjjwal MaheshwariDecember 16, 2025

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Neurizon Therapeutics (ASX: NUZ) just hit a major milestone. The FDA has cleared its lead drug NUZ-001 to enter the HEALEY ALS Platform Trial at Massachusetts General Hospital, with patients now enrolling for this Phase 2/3 study in Q4 2025. This follows the FDA lifting its clinical hold back in October 2025. For investors, the…

ByUjjwal MaheshwariDecember 12, 2025

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at $2.83 per share, a 6% premium to its last close. For a small-cap biotech, that’s unusual; most need to offer discounts to attract funding. This premium placement shows investors are confident about the upcoming HARNESS-1…

ByUjjwal MaheshwariDecember 10, 2025

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Imugene wins FDA support, funding risk remains Imugene (ASX: IMU) received a major regulatory boost this week after the US Food and Drug Administration confirmed support to advance its cancer therapy Azer-Cel into a pivotal Phase 3 study. Written minutes from a November 21 Type C meeting showed clear alignment on trial design, patient population,…

ByUjjwal MaheshwariDecember 9, 2025

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

On Monday December 22, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others will be demoted. It is important to note from the outset the June and December rebalances only involve the ASX 50, ASX 100 and ASX 200 indices whilst the March and September rebalances also involve…

ByNick SundichDecember 9, 2025

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Our 5 ASX Predictions for 2026!

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Stocks in Spotlight

Add Your Heading Text Here